Calcium Dobesilate Prevents Neurodegeneration and Vascular Leakage in Experimental Diabetes

Current Eye Research

Volumn 42, Issue 9, 2017, Pages 1273-1286

  Solà Adell, Cristina ^a,b   Bogdanov, Patricia ^a,b   Hernández, Cristina ^a,b   Sampedro, Joel ^a   Valeri, Marta ^c   Garcia Ramirez, Marta ^a,b   Pasquali, Christian ^d   Simó, Rafael ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Vifor (International) Inc   (Switzerland)

Author keywords

Calcium dobesilate; diabetic retinopathy; retinal neuroprotection; vascular leakage

Indexed keywords

DOBESILATE CALCIUM; ET 1 PROTEIN; ET A RECEPTOR; ET B RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VASCULOTROPIN; HEMOSTATIC AGENT; RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; ENDOTHELIUM CELL; EXPERIMENTAL DIABETES MELLITUS; FUNCTIONAL DISEASE; GENE OVEREXPRESSION; GLIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RETINA NERVE CELL; RISK ASSESSMENT; TREATMENT DURATION; VASCULAR DISEASE; VASCULAR LEAKAGE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; COMPLICATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL PIGMENT EPITHELIUM; TUNEL ASSAY;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM DOBESILATE; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HEMOSTATICS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICROSCOPY, FLUORESCENCE; OXIDATIVE STRESS; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL PIGMENT EPITHELIUM; RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85020230840     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713683.2017.1302591     Document Type: Article

References (52)

1. Congdon NG, Friedman DS, Lietman T., Important causes of visual impairment in the world today. JAMA 2003;290:2057–2060.
2. Fong DS, Aiello LP, Ferris FL, Klein R., Diabetic retinopathy. Diabetes Care 2004;27:2540–2553.
3. Cheung N, Mitchell P, Wong TY., Diabetic retinopathy. Lancet. 2010; 376:124–136.
4. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–564.
5. Simó R, Hernández C., Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res 2015;48:160–180.
6. Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy:therapeutic implications. Br J Ophthalmol 2012; 96:1285–90.
7. Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye:new insights and therapeutic perspectives. Trends Endocrinol Metab 2014;25:23–33.
8. Abcouwer SF, Gardner TW., Diabetic retinopathy:loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci 2014;1311:174–190.
9. Simó R, Ballarini S, Cunha-Vaz J, Ji L, Haller H, Zimmet P, et al. Non-traditional systemic treatments for diabetic retinopathy:an evidence–based review. Curr Med Chem 2015;22:2580–2589.
10. Brunet J, Farine JC, Garay RP, Hannaert P., Angioprotective action of calcium dobesilate against reactive oxygen species–induced capillary permeability in the rat. Eur J Pharmacol 1998;358:213–220.
11. Berthet P, Farine JC, Barras JP., Calcium dobesilate:pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract 1999;53:631–636.
12. Hannaert P, Brunet J, Farine JC, Garay RP., Antioxidant-angioprotective actions of calcium dobesilate in diabetic rats. Int J Angiol 1999;8:2–4.
13. Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 2001;428:277–286.
14. Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 2010;59:2637–2645.
15. Angulo J, Peiró C, Romacho T, Fernández A, Cuevas B, González-Corrochano R, et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011;667:153–159.
16. Rota R, Chiavaroli C, Garay RP, Hannaert P., Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004;495:217–224.
17. Guerrini M, Pieragalli D, Acciavatti A., Calcium dobesilate, hemorheology, fibrinolysis and endothelium. New perspectives on the prevention of diabetic microangiopathy. Clinical pharmacological study. Clin Ter 1989;129:271–285.
18. Vojnikovic B., Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res 1991;23:12–20.
19. Zhong H, Guo L., The plasma levels of endothelin in diabetic retinopathy and their changes after treatment with doxium. Hunan Yi Ke Da Xue Xue Bao 1997;22:56–58.
20. Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh–Jafari H, Ghabili K., Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis 2013;19:62–68.
21. MacCumber MW, D’Anna SA. Endothelin receptor–binding subtypes in the human retina and choroid. Arch Ophthalmol 1994; 112:1231–1235.
22. Stitt AW, Chakravarthy U, Gardiner TA, Archer DB., Endothelin-like immunoreactivity and receptor binding in the choroid and retina. Curr Eye Res 1996;15:111–117.
23. Minton AZ, Phatak NR, Stankowska DL, He S, Ma HY, Mueller BH, et al. Endothelin B receptors contribute to retinal ganglion cell loss in a rat model of glaucoma. PLoS One 2012;7(8):e43199.
24. Chou JC, Rollins SD, Ye M, Batlle DC, Fawzi AA., Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice. Invest Ophthalmol Vis Sci 2014;55:2516–2525.
25. Bogdanov P, Corraliza L, Villena JA, Carvalho AR, Garcia-Arumí J, Ramos D, et al. The db/db mouse:a useful model for the study of diabetic retinal neurodegeneration. PLoS One 2014;9(5):e97302.
26. Hernández C, Bogdanov P, Corraliza L, García-Ramírez M, Solà-Adell C, Arranz JA, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 2016;65:172–187.
27. Padilla E, Ganado P, Sanz M, Zeini M, Ruiz E, Triviño A, et al. Calcium dobesilate attenuates vascular injury and the progression of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev 2005;21:132–142.
28. Anderson PJ, Watts H, Hille C, Philpott K, Clark P, Gentleman MC, et al. Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat. Clin Ophthalmol 2008;2:801–816.
29. Sasaki M, Ozawa I, Kurihara T, Kubota S, Yuki K, Noda K, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 2010;53(5):971–979.
30. Narayan SB, Ditewig-Meyers G, Graham KS, Scott R, Bennett MJ., Measurement of plasma amino acids by Ultraperformance® Liquid Chromatography. Clin Chem Lab Med 2011;49:1177–1185.
31. Perlman I., The electroretinogram:ERG. In:Kolb H, Fernandez E, Nelson R, (Ed). Webvision:The Organization of the Retina and Visual System [textbook online]. Salt Lake City (UT):University of Utah Health Sciences Center; 1995. Available from:http://www.ncbi.nlm.nih.gov/books/NBK11554/
32. Reyland ME., Protein kinase C delta and apoptosis. Biochem Soc Trans 2007;35:1001–1004.
33. Leite EB, Mota MC, de Abreu JR, Cunha-Vaz JG., Effect of calcium dobesilate on the blood–retinal barrier in early diabetic retinopathy. Int Ophthalmol 1990;14:81–88.
34. Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG; DX-Retinopathy, Study Group. Effect of calcium dobesilate on progression of early diabetic retinopathy, a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol 2006;244:1591–1600.
35. Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW, CALDIRET study group. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study):Randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009; 373:1364–71.
36. Zhang X, Liu W, Wu S, Jin J, Wang N., Calcium–dobesilate for diabetic retinopathy, a systematic review and meta–analysis. Sci China Life Sci 2015;58:101–107.
37. Cuevas P, Oteriño LA, Aranza C, Angulo J, Giménez-Gallego G., Improvement of diabetic macular oedema with intravitreal dobesilate:a case report. Austin J Clin Case Rep 2014, 1:1046
38. Cuevas P, Outeiriño LA, Angulo J, Giménez-Gallego G., Chronic cystoid macular oedema treated with intravitreal dobesilate. BMJ Case Rep 2012;2012. pii:bcr2012006376
39. Rauen T, Rothstein JD, Wässle H., Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res 1996; 286:325–336.
40. Sarthy VP, Pignataro L, Pannicke T, Weick M, Reichenbach A, Harada T, et al. Glutamate transport by retinal Muller cells in glutamate/aspartate transporter–knockout mice. Glia 2005;49:184–196.
41. Kobayashi T, Oku H, Fukuhara M, Kojima S, Komori A, Ichikawa M, et al. Endothelin-1 enhances glutamate-induced retinal cell death possibly through ETA receptors. Invest Ophthalmol Vis Sci 2005;46:4684–4690.
42. Cheung SS, Leung JW, Lam AK, Lam KS, Chung SS, Lo AC, et al. Selective over-expression of endothelin-1 in endothelial cells exacerbates inner retinal edema and neuronal death in ischemic retina. PLoS One 2011;6(10):e26184.
43. Tonari M, Kurimoto T, Horie T, Sugiyama T, Ikeda T, Oku H., Blocking endothelin-B receptors rescues retinal ganglion cells from optic nerve injury through suppression of neuroinflammation. Invest Ophthalmol Vis Sci 2012;8:3490–3500.
44. Mi XS, Zhang X, Feng Q, Lo AC, Chung SK, So KF., Progressive retinal degeneration in transgenic mice with overexpression of endothelin-1 in vascular endothelial cells. Invest Ophthalmol Vis Sci 2012;53:4842–4851.
45. Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 2001;428:277–286.
46. Hannaert P, Brunnet J, Farine JC, Garay RP., Antioxidant angioprotective actions of calcium dobesilate in diabetic rats. Int J Angiol 1999;8:S2–S4.
47. Kowluru RA, Mishra M., Oxidative stress, mitochondrial damage and diabetic retinopathy. Biochim Biophys Acta 2015;1852:2474–2483.
48. El–Remessy AB, AlShabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI., Neuroprotective and blood–retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006;168:235–244.
49. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, et al. Activation of PKC–delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009;15:1298–1306.
50. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010; 106:1319–1331.
51. Kim JH, Kim JH, Jun HO, Yu YS, Kim KW., Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Am J Pathol 2010;176:1517–1524.
52. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, et al. Induction of endothelin-1 expression by glucose:an effect of protein kinase C activation. Diabetes 2000;49:1239–1248.